# US 2022/0023212 A1 · Stable formulations of lipids and liposomes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0023212 A1
- Document ID: US20220023212A1
- Status: Published application
- Kind: A1
- Application number: 17/495,104
- Filed: 2021-10-06
- Published: 2022-01-27
- Earliest claimed: 2017-03-13
- Assignees: BioNTech RNA Pharmaceuticals GmbH
- Applicants: BioNTech RNA Pharmaceuticals GmbH
- Inventors: Heinrich Haas; Isaac Hernan Esparza Borquez
- Web page: https://patentgrep.com/patent/US20220023212A1

## CPC

- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to aqueous lipid and/or liposome formulations with an increased chemical stability, to methods of preparing such aqueous formulations as well as to kits comprising them. The present invention further relates to methods of preparing lipid-based pharmaceutical compositions, to pharmaceutical compositions prepared by such methods and to methods of chemically stabilizing aqueous lipid and/or liposome formulations.

## Claims

### Claim 1

An aqueous formulation comprising
at least one lipid having one or more bonds selected from the group consisting of ester bonds, thioester bonds and amide bonds, and
at least one pH adjusting agent,
wherein the aqueous formulation has a pH of between 2 and 5.5.

### Claim 2 (depends on 1)

The aqueous formulation according to claim 1, wherein at least one of the lipids present in the aqueous formulation is a cationic lipid.

### Claim 3 (depends on 1, 2)

The aqueous formulation according to claim 1 or 2, wherein the overall net charge of the lipids present in the aqueous formulation is positive.

### Claim 4 (depends on 1, 2, 3)

The aqueous formulation according to any of claims 1 to 3, having a pH of between 2 and 5, preferably of between 2.5 and 5, more preferably of between 3 and 4.5, more preferably of between 3 and 4, and even more preferably of between 3.5 and 4.

### Claim 5 (depends on 1, 2, 3, 4)

The aqueous formulation according to any of claims 1 to 4, wherein the at least one lipid having one or more bonds selected from the group consisting of ester bonds, thioester bonds and amide bonds comprises a glycerolipid and/or a glycerophospholipid.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The aqueous formulation according to any of claims 1 to 5, wherein the at least one lipid having one or more bonds selected from the group consisting of ester bonds, thioester bonds and amide bonds comprises a cationic lipid and/or a non-cationic lipid.

### Claim 7 (depends on 6)

The aqueous foiiiiulation according to claim 6, wherein the cationic lipid is selected from the group consisting of 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP), 1,2-dioleoyloxy-3-dimethylammoniumpropane (DODAP) and analogues of these molecules having a different composition of the acyl chain moiety.

### Claim 8 (depends on 6, 7)

The aqueous formulation according to claim 6 or 7, wherein the non-cationic lipid is a neutral lipid, wherein, preferably, the neutral lipid is selected from the group consisting of 1,2-di-(9Z-octadecenoyl)-sn-glycero-3 -phosphoethanolamine (DOPE), 1 ,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), phosphatidylcholine (PC) and dimyristoyl phosphatidylcholine (DMPC).

### Claim 9 (depends on 6, 7)

The aqueous formulation according to claim 6 or 7, wherein the non-cationic lipid is an anionic lipid, wherein, preferably, the anionic lipid is selected from the group consisting of phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidic acid (PA), phosphatidylglyerol (PG) and dimyristoyl phosphatidylglyerol (DMPG).

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The aqueous formulation according to any of claims 1 to 9, further comprising at least one lipid not having any ester bonds, thioester bonds or amide bonds.

### Claim 11 (depends on 10)

The aqueous formulation according to claim 10, wherein the at least one lipid not having any ester bonds, thioester bonds or amide bonds comprises a cationic lipid and/or a non-cationic lipid.

### Claim 12 (depends on 11)

The aqueous formulation according to claim 11, wherein the cationic lipid is selected from the group consisting of 1,2-di-O-octadecenyl-3-trimethylammoniumpropane (DOTMA), 1,2-dioleyloxy-N,N-dimethylaminopropane (DODMA), dioctadecyldi-methylammonium (DODA(Br)/DDAB), dioctadecyldimethylammoniumchloride (DODAC), 1,2-dimyristoyloxypropyl-1,3 -dimethylhydroxyethyl ammonium (DMRIE), 2,3 -dioleoyloxy-N-[2(spermine carboxamide)ethyl]-N,N-dimethyl-1-propanamium trifluoroacetate (DOSPA) analogues of these molecules having a different composition of the acyl chain moiety.

### Claim 13 (depends on 11, 12)

The aqueous formulation according to claim 11 or 12, wherein the non-cationic lipid is a neutral lipid, wherein, preferably, the neutral lipid is selected from the group consisting of cholesterol (Chol) and sphingomyelin (SM).

### Claim 14 (depends on 11, 12)

The aqueous formulation according to claim 11 or 12, wherein the non-cationic lipid is an anionic lipid.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The aqueous formulation according to any of claims 1 to 14, comprising at least one cationic lipid and at least one non-cationic lipid.

### Claim 16 (depends on 15)

The aqueous formulation according to claim 15, wherein the molar ratio of the at least one cationic lipid to the at least one non-cationic lipid is from 1:4 to 4:1, preferably from 1:2 to 4:1.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The aqueous formulation according to any of claims 1 to 16, wherein the at least one pH adjusting agent comprises an acid and/or an acidic buffer.

### Claim 18 (depends on 17)

The aqueous formulation according to claim 17, wherein the acid is a linear, branched or cyclic C1-C28, preferably C1-C22, carboxylic acid.

### Claim 19 (depends on 17, 18)

The aqueous formulation according to claim 17 or 18, wherein the acid is selected from the group consisting of acetic acid, ascorbic acid, citric acid, hydrochloric acid, phosphoric acid, branched or unbranched, saturated, monounsaturated or polyunsaturated C12-C28 fatty acids, preferably C12-C22 fatty acids (e.g. oleic acid).

### Claim 20 (depends on 17, 18, 19)

The aqueous formulation according to any of claims 17 to 19, wherein the acidic buffer is based on an acid as defined in claim 17 or 18.

### Claim 21 (depends on 17, 18, 19, 20)

The aqueous formulation according to any of claims 17 to 20, wherein the acidic buffer is selected from the group consisting of acetate buffer, citrate buffer, phosphate buffer and carbonate buffer.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The aqueous formulation according to any of claims 1 to 21, wherein the at least one pH adjusting agent comprises acetic acid and/or acetate buffer.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The aqueous formulation according to any of claims 1 to 22, wherein the at least one pH adjusting agent is present in an amount such that the molar ratio of total lipid to the at least one pH adjusting agent does not exceed 100:1.

### Claim 24 (depends on 23)

The aqueous formulation according to claim 23, wherein the at least one pH adjusting agent is present in an amount such that the molar ratio of total lipid to the at least one pH adjusting agent is from 10:1 to 1:10, preferably from 5:1 to 1:5, more preferably from 2:1 to 1:2, more preferably from 1.5:1 to 1:1.5, even more preferably about 1:1.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The aqueous formulation according to any of claims 1 to 24, wherein the hydrolysis rate of the at least one lipid having one or more bonds selected from the group consisting of ester bonds, thioester bonds and amide bonds is reduced as compared to its hydrolysis rate at a pH of between 6 and 7.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The aqueous formulation according to any of claims 1 to 25, wherein the lipids present in the aqueous formulation form liposomes.

### Claim 27 (depends on 26)

The aqueous formulation according to claim 26, wherein the at least one pH adjusting agent is associated with the liposomes.

### Claim 28 (depends on 26, 27)

A method of preparing an aqueous formulation according to claim 26 or 27, the method comprising
forming the liposomes in an aqueous solution comprising the at least one pH adjusting agent and having a pH of between 2 and 5.5 or
adding the at least one pH adjusting agent to an aqueous solution comprising liposomes in order to adjust the pH of the aqueous solution to a pH of between 2 and 5.5.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A kit comprising an aqueous formulation according to any of claims 1 to 27.

### Claim 30 (depends on 29)

The kit according to claim 29, further comprising, in a separate container, a pharmaceutically active compound, wherein, preferably, the pharmaceutically active compound comprises a nucleic acid, preferably DNA or RNA.

### Claim 31 (depends on 30)

The kit according to claim 30, wherein the nucleic acid is provided in a buffered solution having a pH of between 6 and 8.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A method of preparing a pharmaceutical composition, the method comprising
providing an aqueous formulation according to any of claims 1 to 27; and
mixing the aqueous formulation with a pharmaceutically active compound.

### Claim 33 (depends on 32)

The method according to claim 32, wherein the pharmaceutically active compound comprises a nucleic acid, preferably DNA or RNA, wherein, preferably, the nucleic acid is provided in a buffered solution having a pH of between 6 and 8.

### Claim 34 (depends on 32, 33)

A pharmaceutical composition prepared by the method according to claim 32 or 33.

### Claim 35

A method of chemically stabilizing an aqueous formulation comprising at least one lipid having one or more bonds selected from the group consisting of ester bonds, thioester bonds and amide bonds, the method comprising
adjusting the pH of the aqueous formulation to a pH of between 2 and 5.5.

### Claim 36 (depends on 35)

The method according to claim 35, wherein the chemical stabilization occurs by inhibition of ester bond, thioester bond and/or amid bond hydrolysis.

### Claim 37 (depends on 35, 36)

The method according to claim 35 or 36, wherein at least one of the lipids present in the aqueous formulation is a cationic lipid.

### Claim 38 (depends on 35, 36, 37)

The method according to any of claims 35 to 37, wherein the overall net charge of the lipids present in the aqueous formulation is positive.

### Claim 39 (depends on 35, 36, 37, 38)

The method according to any of claims 35 to 38, wherein the pH is adjusted to a pH of between 2 and 5, preferably of between 2.5 and 5, more preferably of between 3 and 4.5, more preferably of between 3 and 4, and even more preferably of between 3.5 and 4.

### Claim 40 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 35, 36, 37, 38, 39)

The method according to any of claims 35 to 39, wherein the pH of the aqueous lipid formulation is adjusted by adding at least one pH adjusting agent, preferably at least one pH adjusting agent as defined in any of claims 17 to 24.

### Claim 41 (depends on 5, 6, 7, 8, 9, 35, 36, 37, 38, 39, 40)

The method according to any of claims 35 to 40, wherein the at least one lipid having one or more bonds selected from the group consisting of ester bonds, thioester bonds and amide bonds is as defined in any of claims 5 to 9.

### Claim 42 (depends on 35, 36, 37, 38, 39, 40, 41)

The method according to any of claims 35 to 41, wherein the lipids present in the aqueous formulation form liposomes.
